FNAM (Evolutionary Genomics) Total Stockholders Equity: $-5.59 Mil (As of Dec. 2022)


FNAM Evolutionary Genomics Inc FNAM
31 GF Score
Price $0.00
View Full Analysis

What is Evolutionary Genomics Total Stockholders Equity?

Evolutionary Genomics FNAM 31 Total Stockholders Equity is $-5.59 Mil as of Dec. 2022. GuruFocus rates FNAM with a GF Score™ of 31/100.

Evolutionary Genomics's Total Stockholders Equity for the quarter that ended in Dec. 2022 was $-5.59 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Evolutionary Genomics's Book Value per Share for the quarter that ended in Dec. 2022 was $-1.12. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Evolutionary Genomics's Debt-to-Equity for the quarter that ended in Dec. 2022 was -0.67.

Evolutionary Genomics  (OTCPK:FNAM) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Evolutionary Genomics's Book Value per Share for the quarter that ended in Dec. 2022 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-5.592-1.835)/6.655
=-1.12

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Evolutionary Genomics's Debt-to-Equity for the quarter that ended in Dec. 2022 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 3.744) / -5.592
=-0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolutionary Genomics Total Stockholders Equity Related Terms

Evolutionary Genomics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Evolutionary Genomics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolutionary Genomics Total Stockholders Equity Chart

Evolutionary Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.40 -0.33 -1.83 -4.40 -5.59

Evolutionary Genomics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.40 -4.32 -4.77 -5.24 -5.59
FNAM
31GF Score
Evolutionary Genomics Inc FNAM
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $-5.59 Mil mean?
Evolutionary Genomics (FNAM) has a Total Stockholders Equity of $-5.59 Mil as of Dec. 2022. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Evolutionary Genomics and its competitors.
Is Evolutionary Genomics' Total Stockholders Equity too high?
Evolutionary Genomics' current Total Stockholders Equity is $-5.59 Mil. Overall, Evolutionary Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Evolutionary Genomics' Total Stockholders Equity compare to BXRX and GNCA?
Evolutionary Genomics' Total Stockholders Equity of $-5.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Evolutionary Genomics and its competitors. Evolutionary Genomics's current Total Stockholders Equity is $-5.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolutionary Genomics stock overvalued right now?
Evolutionary Genomics (FNAM) has a current Total Stockholders Equity of $-5.59 Mil. The current Total Stockholders Equity is $-5.59 Mil. Evolutionary Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Evolutionary Genomics (FNAM), the current Total Stockholders Equity is $-5.59 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evolutionary Genomics Business Description

Address 4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
31GF Score

Get the complete analysis for FNAM

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price